USE OF CROHNʼS DISEASE MEDICATIONS, INCLUDING INFLIXIMAB, ARE NOT RISK FACTORS FOR THE DEVELOPMENT OF INTESTINAL STRICTURE, STENOSIS OR OBSTRUCTION DATA FROM THE 6000-PATIENT TREAT REGISTRY
Bibliographic record
Abstract
Purpose: Debate exists whether rapid mucosal healing induced by infliximab (IFX) in Crohn's disease (CD) leads to the development or exacerbation of intestinal strictures, stenosis, or obstruction (SSO). The TREAT Registry, an observational study, prospectively assessed the long-term safety of IFX in CD. Methods: More than 6000 patients from North America were enrolled, half of whom received IFX. Treatment choices were made by each patient's physician. Data for the incidence of SSO were analyzed to examine the potential contributory role of IFX as well as other factors. Results: As of February 2004, 6283 patients were enrolled in TREAT with 4247 patient years (pt-yrs) of follow-up for those who received IFX, and 3541 pt-yrs of follow-up for those who received treatments other than IFX. At enrollment, more IFX-treated patients had moderate-to-severe (33.9% vs 11.1%, p <0.0001) or severe-fulminant (2.9% vs 0.6%, p <0.0001) CD; more had been hospitalized (28.9% vs. 19.7%, p <0.0001) or undergone surgery (18.5% vs. 13.7%, p <0.0001) in the previous year; and more were taking corticosteroids (28.4% vs. 16.5%, p <0.0001), or immunomodulators (50.0% vs. 32.9%, p <0.0001). A total of 93 SSO events occurred in patients treated with infliximab, and 41 SSO events occurred in patients treated with other treatments (2.1 events per 100 pt-yrs vs 1.2; RR= 1.89). Multivariate Cox proportional hazards analysis indicated that moderate, severe or fulminant disease (RR = 1.99, 95% CI 1.03-3.81, p <0.05), duration of CD (RR = 1.03, 95% CI 1.003-1.05, p <0.05) and ileal disease (RR = 1.87, 95% CI 1.15-3.03, p <0.05) were predictors of SSO events, but not prior IFX therapy (RR 1.06, 95% CI 0.63-1.79, p = NS), immunomodulator use (RR = 1.40, 95% CI 0.81-2.42, p = NS), or corticosteroid use (RR = 1.62, 95% CI 0.98-2.70, p = NS). Conclusions: The baseline severity of CD, duration of CD and small bowel disease, but not therapy with infliximab, immunomodulators or corticosteroids, were associated with SSO events.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.006 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".